Ausper Biopharma Co., Ltd.

SHANGHAI, Feb. 5, 2026 /PRNewswire/ -- Insight Lifetech, a portfolio company of Qiming Venture Partners and a leading Chinese innovative medical device manfaucturer, successfully listed on the Shanghai Stock Exchange's STAR Market on February 5, 2026 Beijing time. Insight Lifetech (688712.SH) issued shares at a price of CNY17.52 per share and opened at CNY50.31 per share with a market capitalization of CNY20.98 billion. Qiming Venture Partners led the C round financing of Insight Lifetech in 2020 and continued to fund the company's development in the D round. Before the company's IPO, Qiming Venture Partners held a more than 6% stake in Insight Lifetech and was one of its major institutional investors. Founded in 2015, Insight Lifetech is dedicated tondeveloping innovative solutions with the potential to transform precision diagnosis and treatment of cardiovascular diseases. The company is the only domestic medical device company in China with a product portfolio in both precision intravascular physiology and imaging, including the first and only domestic fractional flow reserve (FFR) system approved by NMPA in China, and intravascular ultrasound (IVUS) system, which was the first domestic IVUS system to have entered clinical trialsand completed patient enrollment. Since its establishment, Insight Lifetech has continuously invested in the fields of coronary artery diseases, peripheral vascular diseases, and atrial fibrillation based on the clinical needs of cardiovascular disease diagnosis and the development of cutting-edge technologies. It has now brought 11 products into the market and has more products under development in diverse categories, including IVUS system, FFR system, vascular access products, and electrophysiological solutions, etc. The company's core product, the IVUS system, is the first independently-developed 60MHz high-definition high-speed IVUS product approved in China and the first China-made product approved by CE MDR. The product gained the largest market share in China and reduced the country's dependence on imported products immediately after coming into the market. The FFR system, another core product of the company, is China's first approved domestically-made product in FFR field and the first China-made product approved to to overseas (by CE MDR). The two products are expected to help enhance the clinical practice of precision-guided percutaneous coronary intervention (PCI) surgeries. Song Liang, Founder, Chairman & CEO of Insight Lifetech stated，"Since establishment, Insight Lifetech has consistently adhered to the mission 'To transform healthcare through innovation and quality', dedicating to innovating intelligence-powered precision cardiovascular intervention. With unwavering passion and relentless effort, we have filled a critical gap in China's medical device industry—a sector characterized by the highest technological barriers and the longest industrial chain: high-performance precision cardiovascular interventional devices. Moving forward, we will continue to hold our position at the forefront of innovation in precision cardiovascular intervention, remain clinically focused, pursue uncompromising quality, and demonstrate the robust power of Chinese innovation to the world. " "Insight Lifetech is deeply committed to transfer clinical insights and technological capabilities to innovative and differentiated ntherapies in the cardiovascular intervention field, for the benefits of patients and physicians, worldwide. The dedicated team convinced us that it can make continuous breakthroughs in the field of innovative medical devices. The successful IPO of Insight Lifetech is not only an important verification of the development path of domestic cardiovascular innovative medical devices, but also demonstrates the rapid rise of China's global competitiveness in medtech innovation. Qiming Venture Partners believes that China's clinical experience, engineering capabilities, and entrepreneurship as well as advantages in supply chains can cultivate a generation of innovative medical device products which are competitive worldwide. We hope to work with ambitious entrepreneurs, to develophigh-quality products, and to co-build great medical device companies from China," Oscar Zhang, a partner of Qiming Venture Partners, said. About Qiming Venture Partners Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Healthcare industries at the early and growth stages. Since our debut, we have backed over 580 fast-growing and innovative companies. Over 210 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 80 portfolio companies that have achieved unicorn or super unicorn status. Many of our portfolio companies are today's most influential firms in their respective sectors, including Xiaomi, Meituan, Bilibili, Zhihu, Roborock, Hesai Technology, UBTech, WeRide, HyperStrong, Insta360, Unisound, Biren Technology, Z.ai, Gan & Lee Pharmaceuticals, Tigermed, Zai Lab, CanSino Biologics, Schrödinger, APT Medical, Sanyou Medical, AmoyDx, SinocellTech, Insilico Medicine, AusperBio, Yuanxin Technology, Medilink Therapeutics, LaNova Medicines, StepFun, among many others. 21% more press release views with Request a Demo

SHANGHAI, Dec. 30, 2025 /PRNewswire/ -- Insilico Medicine (03696.HK), a global leader in AI-driven drug discovery and a portfolio company of Qiming Venture Partners, today successfully listed on the Hong Kong Stock Exchange (HKEX). The listing marks the largest biotech IPO on the Hong Kong stock market in 2025. With an issue price of HK$ 24.05 per share, Insilico Medicine opened at HK$35.00 per share, representing a market capitalization of approximately HK$ 19.51 billion. Qiming Venture Partners is one of Insilico Medicine's most important institutional investors. Qiming Venture Partners led the Company's Series B financing round in 2019 and continued its support in subsequent Series C and D rounds, with an about 7 percent stake in Insilico Medicine before its IPO. Founded in 2014, Insilico Medicine employs a business model based on the Pharma.AI platform, focuses on internal drug research and development through artificial intelligence. It has gradually expanded the application of Pharma. AI to more industries such as advanced materials, agriculture, nutritional products, and veterinary drugs. It has now efficiently built a pipeline portfolio covering over 30 innovative projects in a wide range of fields with extensive demands, such as oncology, immunology, fibrosis, and metabolism, and owns the world's most advanced first-in-class AI-based drugs. To date, 13 of the world's top 20 pharmaceutical companies by revenue have entered into software platform collaborations with Insilico Medicine. Insilico Medicine has also reached licensing agreements on three pipelines with global drugmakers such as Exelixis and Menarini, bringing a potential revenue of USD2 billion for the company. The Company has also established drug R&D partnerships with other internationally renowned pharmaceutical firms including Sanofi, Lilly, and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. "Insilico is dedicated to extending human productive longevity and this listing provides us with more resources to advance our mission. Over the past few years, we set very clear industry benchmarks demonstrating that AI can help make drug discovery faster, cheaper, and deliver higher success rates in preclinical and early clinical development. We have validated the end-to-end capabilities of AI-empowered programs from novel target discovery to molecular generation, and then to preclinical and clinical stages. Going forward, we will continue to increase investment in our AI platform and innovative pipeline, accelerate the advancement of differentiated innovative programs into clinic, and bring truly accessible, affordable, and breakthrough treatment solutions to patients worldwide." said Alex Zhavoronkov, PhD, Founder and CEO, Chief Business Officer of Insilico Medicine. "We invest in Insilico Medicine based on a simple belief that 'AI will profoundly change the pathway and efficiency of drug development.' We decided to invest in Insilico Medicine in 2019 because of its research in frontier areas when generative AI was not yet popularized. Now the value of Insilico Medicine in the field of AI pharmaceuticals is gradually being realized through preclinical validation and pipeline licensing. We expect AI to not only empower early-stage research and development but also effectively accelerate the clinical stage process in the future to enable new drugs to benefit patients earlier," Dr. Chen Kan, Partner and Healthcare Co-Lead at Qiming Venture Partners, said. About Qiming Venture Partners Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Healthcare industries at the early and growth stages. Since our debut, we have backed over 580 fast-growing and innovative companies. Over 210 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 80 portfolio companies that have achieved unicorn or super unicorn status. Many of our portfolio companies are today's most influential firms in their respective sectors, including Xiaomi, Meituan, Bilibili, Zhihu, Roborock, Hesai Technology, UBTech, WeRide, HyperStrong, Insta360, Unisound, Gan & Lee Pharmaceuticals, Tigermed, Zai Lab, CanSino Biologics, Schrödinger, APT Medical, Sanyou Medical, AmoyDx, SinocellTech, Insilico Medicine (SEHK:03696), AusperBio, Yuanxin Technology, Medilink Therapeutics, LaNova Medicines, zai, StepFun, among many others. SOURCE Qiming Venture Partners 21% more press release views with Request a Demo

SAN FRANCISCO, Dec. 22, 2025 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company developing targeted oligonucleotide therapies for functional cure of chronic hepatitis B (CHB), today announced the completion of patient enrollment in its P hase III AUSHINE clinical trial (CTR20252792/ NCT07246889). The AUSHINE study is a randomized, double-blind, multicenter Phase III trial evaluating the efficacy and safety of AHB-137 injection in participants with HBeAg-negative CHB treated with nucleos(t)ide analogue (NA) therapy. CHB remains a major global public health challenge. According to the World Health Organization (WHO) Global Hepatitis Report 2024, approximately 254 million people worldwide are living with hepatitis B virus (HBV), and 1.2 million people are newly infected annually with HBV. In China alone, an estimated 75 million are chronically infected1. Professor Jian Sun, principal investigator and President of Nanfang Hospital, Southern Medical University, commented, "For the vast majority of HBeAg-negative CHB patients receiving long-term nucleos(t)ide analogue therapy, treatment today is only suppressive rather than curative. Functional cure remains an urgent unmet goal for this large patient population, most of whom face lifelong therapy with ongoing risk of disease progression. The completion of enrollment in this pivotal Phase III study is a critically important step towards addressing this gap, and we are eager to see if the novel, triple-mechanistic approach of this ASO therapy can unlock a new path to functional cure for our patients." Dr. Guofeng Cheng, Co-founder and CEO of AusperBio, commented, "The successful enrollment of over 570 patients ahead of schedule marks a critical milestone in our mission to advance a functional cure for chronic hepatitis B. Full enrollment was achieved within five months of China CDE approval, reflecting the strong engagement and dedication of the investigators, patients, clinical teams who partnered with us in this program. We are deeply grateful and remain firmly committed to advancing AHB-137 through a rigorous registrational pathway, guided by strong science and a clear focus on delivering a paradigm-shifting treatment for people living with chronic hepatitis B." Dr. Chris Yang, Co-founder and CSO of AusperBio, added, "Completing enrollment of the Phase III AUSHINE study within 2025 exceeded our initial expectations and positions the program for rapid progression toward its primary endpoint readout. The pace of enrollment and strong interest from clinical sites reflect both the urgent needs for novel HBV treatment and the promising efficacy and safety profile of AHB-137. The encouraging clinical efficacy observed to date, including a functional cure rate of approximately 30% recently presented at the HEP-DART 2025 conference, reinforces our confidence in the triple-mechanistic activities of AHB-137 and its potential to deliver functional cure for CHB patients." About AHB-137 AHB-137 is a novel unconjugated antisense oligonucleotide ( ASO) designed using AusperBio's proprietary Med-Oligo™ ASO technology platform and is designed to achieve functional cure of CHB. Its mechanism integrates three complementary actions: targeted suppression of HBsAg at the transcriptional level, inhibition of viral DNA replication, and immune reactivation. AHB-137 has demonstrated promising preclinical and clinical results, with key findings presented at major international hepatology congresses including EASL (2023 - 2025), AASLD (2024 - 2025), and APASL (2025). AHB-137 has completed a global Phase I study and is currently being evaluated in multiple Phase II studies and a phase III trial in China. Supported by a coordinated global development strategy, AHB-137 is advancing toward its goal of delivering a potential functional cure for HBV infection. About AusperBio AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China, dedicated to advancing oligonucleotide and targeted delivery technologies for transformative therapies, with an initial focus on achieving functional cure for CHB infection. The company has developed a proprietary Med-Oligo™ ASO platform which has been shown to substantially enhance the current ASO therapeutics, through novel insights into ASO design. Combining efficient targeted delivery conjugation technologies, the modular Med-Oligo™ platform empowers ASO therapeutics to treat a broad range of diseases, including viral infections, muscle disorders, and immune diseases. For more information, visit Reference： 1、 Wang, X., Li, Y., & Zhang, H. (2024). Prevalence of chronic hepatitis B virus infection in China: A national cross-sectional study. The Lancet Regional Health - Western Pacific, 50, 101234. *This press release is prepared by AusperBio (the "Company", "We") for informational purposes only. Forward-looking statements include all statements that are not historical facts, and in some cases, can be identified by terms such as "anticipate", "expect", "intend", "plan", "believe", "continue", "could", "potential", "may", "will", "goal" or similar expressions and the negatives of those terms. However, not all forward-looking statements contain these identifying words. These forward-looking statements involve substantial known and unknown risks and uncertainties, including the risk that results in earlier clinical studies may not be indicative of future results and that any product candidates may not ultimately obtain required approvals or meaningfully improve patient outcomes, and other factors that are beyond the Company's control and are difficult to predict and may cause our actual results, timing of results, or achievements to be materially different from the information expressed or implied by these forward-looking statements. We anticipate that subsequent events and developments may cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. Except as expressly required by law, the Company and/or its officers, directors, employees, and agents shall not assume responsibility for the accuracy and completeness of the forward-looking statements in the information provided. Media Contact Email: [email protected] Investor Contact Tel: 650-888-1756 (US) Email: [email protected] SOURCE AusperBio Therapeutics Inc. 21% more press release views with Request a Demo